Changes in neuromuscular structure and functions of human colon during ageing are region-dependent

How to cite:

Broad, John; Kung, Victor W. S.; Palmer, Alexandra; Elahi, Shezan; Karami, Azadeh; Darreh-Shori, Taher; Ahmed, Shafi; Thaha, Mohamed Adhanan; Carroll, Rebecca; Chin-Aleong, Joanne; Martin, Joanne E.; Saffrey, M. Jill; Knowles, Charles H. and Sanger, Gareth John (2018). Changes in neuromuscular structure and functions of human colon during ageing are region-dependent. Gut (Early Access).

For guidance on citations see FAQs.

© 2018 The Authors

Version: Version of Record

Link(s) to article on publisher’s website:
http://dx.doi.org/10.1136/gutjnl-2018-316279

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies page.
Changes in neuromuscular structure and functions of human colon during ageing are region-dependent

John Broad,1 Victor W S Kung,1 Alexandra Palmer,1 Shezan Elahi,1 Azadeh Karami,2 Taher Darreh-Shori,2 Shafi Ahmed,3,4 Mohamed Adhnan Thaha,1,3,4 Rebecca Carroll,1 Joanne Chin-Aleong,1 Joanne E Martin,1 M Jill Saffrey,5 Charles H Knowles,1,3,4 Gareth John Sanger1

ABSTRACT

Objective To determine if human colonic neuromuscular functions decline with increasing age.

Design Looking for non-specific changes in neuromuscular function, a standard burst of electrical field stimulation (EFS) was used to evoke neurally mediated (cholinergic/nitrergic) contractions/relaxations in ex vivo muscular strips of human ascending and descending colon, aged 35–91 years (macroscopically normal tissue; 239 patients undergoing cancer resection).

Then, to understand mechanisms of change, numbers and phenotype of myenteric neurons (30 306 neurons stained with different markers), densities of intramuscular nerve fibres (51 patients in total) and pathways involved in functional changes were systematically investigated (by immunohistochemistry and use of pharmacological tools) in elderly (≥70 years) and adult (35–60 years) groups.

Results With increasing age, EFS was more likely to evoke muscle relaxation in ascending colon instead of contraction (linear regression: n=109, slope 0.49±0.21%/year, 95% CI), generally uninfluenced by comorbidity or use of medications. Similar changes were absent in descending colon. In the elderly, overall numbers of myenteric and neuronal nitric oxide synthase-immunoreactive neurons and intramuscular nerve densities were unchanged in ascending and descending colon, compared with adults. In elderly ascending, not descending, colon numbers of cell bodies exhibiting choline acetyltransferase immunoreactivity increased compared with adults (5.0±0.6 vs 2.4±0.3 neurons/mm myenteric plexus, p=0.04). Cholinergically mediated contractions were smaller in elderly ascending colon compared with adults (2.1±0.4 and 4.1±1.1 g-tension/g-tissue during EFS; n=25/14; p=0.04); there were no changes in nitrergic function or in ability of the muscle to contract/relax. Similar changes were absent in descending colon.

Conclusion In ascending but not descending colon, ageing impairs cholinergic function.

INTRODUCTION

There is evidence that human GI functions change in the elderly (>65–70 years),1 contributing to the development of constipation with associated pain, loss of dignity, reduced quality of life, faecal impaction and incontinence.1,2 Approximately 30%–40% of people aged 65 years or older self-report constipation.3 However, other factors are important, including changes in diet, fluid intake, exercise, bowel disorders (eg, diverticulitis or bowel cancer) and use of medications that reduce

Significance of this study

What is already known on this subject?

► Studies in ageing rodents suggest loss of myenteric neurons and a decline in cholinergic function of the colon. However, not all studies agree and uncertainty exists in terms of how these findings translate to humans.

► Studies using human colon have generally used small numbers of tissues with variable or undefined clinical history and heterogeneous techniques, generating inconsistent data.

► Nevertheless, a decline in neuromuscular functions has been suggested to contribute to the mechanisms underlying the increased incidence of constipation among the elderly.

What are the new findings?

► In a large functional study (ascending/descending colon from, respectively, 109 and 130 patients), increasing age increased the likelihood that electrical nerve stimulation caused muscle relaxation in ascending colon, instead of contraction, but no age-related changes were observed in descending colon.

► The functional changes with increasing age were not explained by loss of neurons within the myenteric plexus, reduced density of intramuscular axon bundles or changes in numbers of nitrergic neurons, but were associated with an increase in choline acetyltransferase (ChAT) immuno-positive myenteric nerve cell bodies in ascending, not descending colon.

► Functional changes with increasing age were explained by a decline in cholinergic function in ascending but not in descending colon (allowing an unchanged nitrergic function to exert greater inhibitory influence on cholinergic activity).

► There were no regional or age-related differences in the ability of the smooth muscle to contract or relax.
GI motility (eg, opioid-based analgesics, tricyclic antidepressants, calcium-channel antagonists). In rodents, declining colonic neuromuscular functions are reported during increasing age; some (not all) report reduced numbers of myenteric cholinergic neurons and glial cells, reduced mucosal secretory capacity and slower intestinal transit. However, caution is required when translating such data to humans. Rodents have high metabolic rates, relatively short life spans and GI physiology distinct from primates, with functional disparities reflected by differences in anatomy, neuronal functions, receptor pharmacology and molecular structures. Further complications are caused by genetic variation between different strains of laboratory rodents, including differences in loss of myenteric nitrergic neurons during advanced age. Alternative use of baboons does not entirely remove translational uncertainty (the colon has adapted to fruit and vegetable diets and myenteric nitrergic neurons during advanced age). Alternative use of baboons does not entirely remove translational uncertainty (the colon has adapted to fruit and vegetable diets and myenteric nitrergic neurons during advanced age). Alternative use of baboons does not entirely remove translational uncertainty (the colon has adapted to fruit and vegetable diets and myenteric nitrergic neurons during advanced age).

This study aimed to determine if age-associated changes in neuromuscular functions can be identified using ex vivo preparations of human ascending and descending colon and then determine mechanisms of change by multiple, systematic anatomical and pharmacological approaches.

MATERIALS AND METHODS

Patients and tissues

After ethical approval (REC 10/H0703/71), written informed consent was obtained for use of macroscopically normal ascending and descending/sigmoid (referred to hereon as descending) colon (5–10 cm from tumour) from patients undergoing elective surgery for non-obstructing bowel cancer. Patient records were examined for ongoing medication and comorbidity; clinical investigations into bowel functions were not conducted. No patient had previous chemoradiotherapy or diagnosis of inflammatory bowel disease. Tissue was immersed into preoxygenated Krebs solution 60–120 min after surgery. When investigating mechanisms, two discontinuous age groups were studied, either side of the overall median age of patients examined: adult (35–60 years) and elderly (≥70 years).

Anatomical studies

Histopathology

Full thickness tissues, orientated to demonstrate mucosal, submucosal, muscularis and serosal layers, −1×1 cm, were fixed and embedded in paraffin blocks prior to cutting into multiple 4 µm thick sections. Sections were stained with H&E for routine histopathological assessment. Significant inflammation was excluded by observation of crypt architecture, distortion and atrophy, lamina propria cellularity, basal plasmacytosis, active inflammation, granulomata, mucin depletion, crypt abscesses, cryptitis and ulceration.

Myenteric neuronal quantitation

Neurons were immunostained using anti-human neuronal protein C/D (anti-Hu/C/D; pan-neuronal antigen for cytoplasmic RNA-binding proteins, labelling cell nucleus and perikaryon), anti-choline acetyltransferase (anti-ChAT) and anti-neuronal nitric oxide synthase (anti-nNOS). For each, a median of seven sections were examined for each patient (so not less than 10 mm of stained myenteric plexus could be studied, usually more). Each section was cut from the same block (minimum 16 µm separation). Following antigen retrieval and visualisation, cell nuclei were counterstained with hematoxylin. Positive and negative controls were performed in colon (anti-Hu/C/D, anti-nNOS) and spinal cord (anti-ChAT), with or without primary antibodies. Stained slides were scanned and digitally visualised.

For neuronal quantitation, a line was drawn along the myenteric plexus (freehand draw function in viewing software). For ganglion counts, sections stained with anti-Hu/C/D were viewed at 40× magnification. To quantify cell bodies within each ganglion, sections stained with anti-Hu/C/D were viewed at 60××80× magnification. Subclasses of myenteric cell bodies were counted separately after staining with anti-ChAT and anti-nNOS. Counting of ganglia and cell bodies and other assessments of staining were performed by two independent observers ‘blinded’ to patient identity/age (online supplementary file 1).

Densitometric analysis of intramuscular nerve fibre bundles

Sections were labelled using anti-protein gene product 9.5 (anti-PGP9.5) (online supplementary file 1) to examine changes in axons/nerve fibre bundles in the muscle. Stained slides were scanned, digitally visualised and two non-adjacent areas from each of three different regions investigated per section: circular

Table 1 Patients and tissues used

<table>
<thead>
<tr>
<th>Region of colon</th>
<th>All tissues studied</th>
<th>Gender (male:female)</th>
<th>Tissues used for functional studies</th>
<th>Tissues used for H&amp;E staining</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Age (years)</td>
<td>n (strips)</td>
<td>Age (years)</td>
</tr>
<tr>
<td>Ascending</td>
<td>113</td>
<td>69±1 (35–91)</td>
<td>0.7: 1</td>
<td>109 (1020)</td>
</tr>
<tr>
<td>Descending/sigmoid</td>
<td>132</td>
<td>65±1 (35–91)</td>
<td>1: 4: 1</td>
<td>130 (1276)</td>
</tr>
</tbody>
</table>

n, number of patients (for functional studies, numbers of muscle strips used are given in parenthesis). The ages of the patients are given as mean±SEM with ranges in parenthesis. For functional studies, tissues were used after overnight storage in fresh Krebs solution at 4°C (188 tissues), 44 on the day of surgery and 7 on the day of surgery and after storage.
Figure 1  The effects of electrical field stimulation (EFS) in circular muscle of ascending and descending colon from adult (35 to 60 years) and elderly (≥70 years) patients. Panel A shows representative trace examples illustrating responses during and after termination of EFS over a range of frequencies of stimulation. EFS was applied at 1–20 Hz and at 50 V for 10 s every 1 min. Using tissues from the adult group, panel B shows the overall contraction force (mean±SEM g tension/g wet weight of tissue) generated during EFS in both regions of colon for each frequency of stimulation in the presence of vehicle, tetrodotoxin (TTX) 1 µM, atropine 1 µM or L-NAME (Nω-nitro-L-arginine methyl ester hydrochloride) 300 µM (n=5 each). Panels C and D show responses to EFS at 5 Hz, 50 V for 10 s, repeated every 1 min. The individual trace in panel C illustrates the ability of TTX 1 µM to inhibit responses evoked by repeated EFS. In panel D, the effects of single bursts of EFS are shown before and after treatment with atropine 1 µM or L-NAME 300 µM, in two muscle strips cut from the same tissue (male, 74, descending colon). The 10 s period of EFS is indicated by the horizontal bars (note the expanded time scale relative to panel C). Atropine inhibited contractions during EFS and decreased after-contractions. L-NAME inhibited relaxations during EFS and facilitated contraction amplitudes.
muscle near myenteric plexus, circular muscle close to the mucosa (deep circular muscle) and longitudinal muscle.

Cholinergic enzyme assays
ChAT, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) expression and activity in colon muscle were measured as previously described (online supplementary file 2).

Functional studies
Detailed methods have been described previously. In brief, after removing the mucosa, strips were cut parallel to the circular muscle (~5 mm wide, 10–15 mm long; 3–31 from each patient) and mounted in warmed tissue baths containing Krebs solution (mmol/L: NaCl 121.5, CaCl₂ 2.5, KH₂PO₄ 1.2, KCl 4.7, MgSO₄ 1.2, NaHCO₃ 25, glucose 5.6, equilibrated with 5% CO₂/95% O₂) for measuring isometric muscle tension. After 1-hour recovery, electrical field stimulation (EFS) was applied and consistent responses obtained.

Responses to EFS were analysed qualitatively by counting numbers of tissues relaxing or contracting. Quantitative measurements were of changes in tension/gram (g) wet weight of tissue; contractions were assigned positive values and relaxations negative values (if relaxation followed contraction, assignment was to the movement of greatest magnitude). Drug-induced changes were differences between the mean of three responses before and 30 min after drug application. In determining the effects of L-NAME (Nω-nitro-L-arginine methyl ester hydrochloride) and atropine (inhibiting, respectively, nitrergic and cholinergic functions in human colon), one strip/patient was selected from multiple strips/patient exposed to these drugs for a number of different studies (computer random number generation). Similarly, when determining the influence of age on these responses, strips were randomly selected to match the proportions of phenotype (contraction/relaxation in response to EFS) observed in each region of colon. Non-cumulative concentration–response curves were measured for carbachol (muscarinic M₁–M₅ receptor agonist) and sodium nitroprusside (SNP; nitric oxide (NO) donor) were measured by applying single concentrations for 15 min or until maximum effect was observed (online supplementary file 3 shows carbachol concentration–response curves).

Drugs were freshly prepared prior to use. Carbachol, atropine, L-NAME, SNP and DEA-NO (diethylamine NONOate; diethylammonium (Z)−1-(N,N-diethylamino)diazen-1-ium-1,2-diolate; Sigma, UK), MRS2500 (P2Y₁ receptor antagonist in human colon) and tetrodotoxin (TTX; Tocris, UK) were dissolved in distilled water. The L-type calcium channel stabiliser (S)-ω-Bay K8644 was dissolved in dimethyl sulfoxide (DMSO) (Sigma) to 10 mM. A cocktail of neurokinin (NK)₃, NK₁, and NK₂ receptor antagonists was prepared by dissolving L732138 (Tocris) in DMSO, GR159897 (Tocris) and SB233575 (GSK) in ethanol, each to 10 mM, for use at, respectively, 1 μM, 0.1 μM and 0.1 μM bath concentrations, inhibiting tachykinergic functions in human colon.

Statistical analysis
To test whether patient characteristics affected responses to EFS, measured initially when surveying the effects of age, contingency analyses (χ² or Fisher’s exact test) were applied as a screening test to two groups (higher or lower than the mean percentage strip relaxation of adult ascending colon), with a conservative level of statistical significance used (p≤0.01) to allow for multiple comparisons. On the basis that only one of the 130 covariates evaluated appeared to confound results, multivariable analyses were not performed.

In mechanism-based functional experiments, EC₅₀ and Eₘₐₓ values were obtained from three-parameter agonist–response curves using GraphPad Prism 7.02. Data are expressed as means±SEM. The n values represent number of patients. Differences between means were determined using analyses of variance (ANOVA) with Sidak’s multiple comparisons test for unpaired observations. P value <0.05 represented statistical significance.

For anatomical studies, numbers of cell bodies were expressed per millimetre of myenteric plexus. Inter-rater differences (95% CI) were analysed using one-sample Student’s t-tests and proportional biases investigated using Bland-Altman plots (online supplementary file 1). For comparisons, normality testing (D’Agostino & Pearson) was performed and neurons/mm length analysed for differences in means using ANOVAs with Sidak’s multiple comparisons test (11/12 variables were normally distributed). P value <0.05 represented statistical significance.

RESULTS
Patients
Two hundred and forty-five patients (122 women; mean age 66 (range 35–91) years) consented to provide fresh surgical colon (table 1). On H&E staining, only a minority of adult and elderly patients showed low-grade inflammation limited to the mucosa.

---

**Table 2** Pharmacology of responses to EFS in circular muscle from human adult ascending and descending colon

<table>
<thead>
<tr>
<th>Drug</th>
<th>Response</th>
<th>Adult ascending</th>
<th>Adult descending</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>During EFS (g/g tension)</td>
<td>After EFS (g/g tension)</td>
<td>During EFS (g/g tension)</td>
</tr>
<tr>
<td>Atropine 1 μM</td>
<td>Contraction prevented during EFS, revealing or enhancing relaxation; contractions after EFS attenuated</td>
<td>−2.6±1.0 (6)</td>
<td>−1.8±0.8 (4)</td>
</tr>
<tr>
<td>Atropine plus NK₁–₅</td>
<td>As above but with consistent inhibition of contractions after EFS</td>
<td>−4.4±2.1 (5)</td>
<td>−1.5±0.5 (3)</td>
</tr>
<tr>
<td>L-NAME 300 μM</td>
<td>Contraction during EFS increased in ascending colon only; no consistent effect on contractions after EFS</td>
<td>3.2±1.1 (14)</td>
<td>−0.2±1.2 (7)</td>
</tr>
<tr>
<td>MRS2500 1 μM</td>
<td>No consistent change during and after EFS</td>
<td>0.8±0.5 (5)</td>
<td>0.1±0.3 (3)</td>
</tr>
</tbody>
</table>

EFS was applied at 5 Hz, 50 V for 10 s, repeated every 1 min. The effects of treatment with atropine, NK₁–₅, receptor antagonists (L732138 1 μM, GR 159897 0.1 μM and SB-233575 0.1 μM, applied together and in the presence of atropine), L-NAME and MRS2500 are shown for the responses during and after EFS. Data are given as the decrease or increase in mean±SEM of the overall muscle tension during each phase of EFS, expressed as g tension/g wet weight of tissue. The n values (in parenthesis) refer to numbers of patients; since after-contractions were not consistently observed in tissues from all patients, these were sometimes smaller.

EFS, electrical field stimulation; L-NAME, Nω-nitro-L-arginine methyl ester hydrochloride.
Age-related changes in overall function

Before examining mechanisms of change we looked for existence of any non-specific change in neuromuscular function, using a standard burst of EFS to evoke neurally mediated contractions/relaxations in muscle strips from large numbers of human ascending and descending colon over a wide age range (35–91 years).

Preliminary experiments

To determine the optimal frequency to study, frequency–response curves were constructed using adult (n=34) and elderly (n=58) tissues (females and males assessed together). In adult ascending/descending colon, 1–20 Hz EFS usually caused contraction often followed by after-contraction on termination of EFS (figure 1A).

TTX 1 µM prevented responses to 1–5 Hz EFS, but small monophasic contractions remained at higher frequencies (figure 1B). L-NAME 300 µM prevented any relaxations and increased the amplitude of contractions during EFS. Atropine 1 µM prevented contractions during EFS, revealing small muscle relaxations, particularly in ascending colon (figure 1B). Compared with adults, ascending colon from the elderly exhibited little or no muscle movement during 1–2 Hz EFS and contractions during 5–20 Hz appeared smaller (respectively n=19, 32; there were no age-dependent differences in after-contractions), whereas in descending colon from the elderly, any effects of increasing age were unclear (n=12–26; online supplementary file 4).

These small numbers of patients precluded meaningful statistical analyses. However, they supported initiation of a larger study to examine changes in overall function.
investigation in which EFS was applied at the single frequency of 5 Hz, evoking a robust, TTX (1 µM)-sensitive muscle contraction or relaxation, usually followed by a large after-contraction (figure 1D). It was confirmed that atropine 1 µM and L-NAME 300 µM prevented, respectively, contractions and relaxations during EFS, enhancing the opposing response (figure 1D, table 2). Atropine also reduced the amplitude of any after-contractions, reduced further by NK1,2,3 receptor antagonism; MRS2500 1 µM had no consistent effects (table 2).

Age-dependent changes in neuromuscular responses
During EFS at 5 Hz, the occurrence of contractions or relaxations sometimes varied among different muscle strips from the same colon (figure 1D). To investigate the effects of advancing age, a mean of 10 strips (3–31 from each patient, depending on tissue availability) were examined (239 patients). The numbers of strips relaxing or contracting during EFS, and contracting tissue availability) were examined (239 patients). The numbers of strips relaxing or contracting during EFS, and contracting after EFS, were expressed as the percentage total for that patient (note: the number of strips used from each region of colon was similar and showed no age-dependent selection bias; data not shown).

Advancing age (35 to 91 years) increased the likelihood that muscle relaxation, rather than contraction, occurred during EFS in ascending colon (figure 2A,C). In descending colon, there were no age-related changes in responses evoked during EFS (figure 2B,C) and the incidence of after-contractions was unchanged in either region of colon (figure 2C).

Multivariate logistic regression showed these results were largely unaffected by clinical variables with known potential to affect colon functions (table 3, online supplementary file 5) although use of α-adrenoceptor antagonists appeared associated with reduced occurrence of muscle relaxation during EFS.

Subsequent studies to examine mechanisms of change were conducted using two discontinuous age groups (35–60 and ≥70 years), either side of the median age.

Mechanisms: anatomical
Myenteric neuronal cell bodies staining for nNOS and ChAT
In 36 patients (8 adult, 9 elderly ascending; 9/10 adult/elderly descending), a mean of 36 mm of myenteric plexus/antibody/patient was sampled and 30306 myenteric neurons counted (646 sections). 18383 neurons were stained for HuC/D (3520/3104 adult/elderly ascending, 6580/5634 descending), ChAT (5047 neurons, respectively, 827/1153 and 1711/1356) and nNOS (6421 neurons, respectively, 1627/1235 and 1743/1816). Reported changes were not influenced by interobserver differences (online supplementary file 1).

Figure 3A shows examples of labelled sections; table 4 provides a summary. In adults, there appeared to be fewer myenteric ganglia and a smaller number of nerve cell bodies (corresponding to a smaller number of ChAT-staining cells) in ascending, relative to descending colon (respectively, n=8, 9 patients); these numbers did not change with increasing age (figure 3B; respectively, n=9, 10). Compared with other antibodies, the signal-to-background

Table 3  Contingency analyses to identify effect of patient state and trait variables on responses evoked by 5 Hz EFS in the ascending colon (n=109)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Muscle relaxation</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medications</td>
<td>No (n=49)</td>
<td>Yes (n=60)</td>
</tr>
<tr>
<td>Regular laxative use</td>
<td>3 (6.1%)</td>
<td>6 (10.0%)</td>
</tr>
<tr>
<td>Opiates</td>
<td>7 (14.3%)</td>
<td>8 (13.3%)</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>11 (22.4%)</td>
<td>13 (21.7%)</td>
</tr>
<tr>
<td>Anticholinergic drugs†</td>
<td>5 (10.2%)*</td>
<td>11 (18.3%)</td>
</tr>
<tr>
<td>Calcium channel blocker</td>
<td>8 (16.3%)</td>
<td>13 (21.7%)</td>
</tr>
<tr>
<td>Diuretics</td>
<td>13 (26.5%)</td>
<td>13 (21.7%)</td>
</tr>
<tr>
<td>Beta blocker</td>
<td>9 (18.4%)</td>
<td>11 (18.3%)</td>
</tr>
<tr>
<td>Anti-arrhythmics</td>
<td>0</td>
<td>1 (1.7%)</td>
</tr>
<tr>
<td>Inhaled</td>
<td>1 (2.0%)</td>
<td>8 (13.3%)</td>
</tr>
<tr>
<td>S-alpha reductase inhibitor</td>
<td>3 (6.1%)</td>
<td>0</td>
</tr>
<tr>
<td>Cation-containing agents</td>
<td>11 (22.4%)</td>
<td>16 (26.7%)</td>
</tr>
<tr>
<td>Bisphosphonates</td>
<td>2 (4.1%)</td>
<td>4 (6.7%)</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>0</td>
<td>1 (1.7%)</td>
</tr>
<tr>
<td>Alpha blockers†</td>
<td>10 (20.4%)</td>
<td>2 (3.3%)</td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diverticular disease</td>
<td>1 (2.0%)</td>
<td>5 (8.3%)</td>
</tr>
<tr>
<td>Previous abdominal or pelvic surgery</td>
<td>12 (24.5%)</td>
<td>14 (23.3%)</td>
</tr>
<tr>
<td>Conditions affecting central nervous system</td>
<td>7 (14.3%)</td>
<td>10 (16.7%)</td>
</tr>
<tr>
<td>Psychiatric conditions</td>
<td>6 (12.2%)</td>
<td>4 (6.7%)</td>
</tr>
<tr>
<td>Diverticular disease</td>
<td>10 (20.4%)</td>
<td>9 (15.0%)</td>
</tr>
<tr>
<td>Any thyroid conditions</td>
<td>2 (4.1%)</td>
<td>5 (8.3%)</td>
</tr>
<tr>
<td>Cardiovascular conditions</td>
<td>12 (24.5%)</td>
<td>14 (23.3%)</td>
</tr>
</tbody>
</table>

The table shows the numbers of patients (with percentage of total) with each factor.

*Contingency comparisons are shown using Fisher’s exact test or χ² test (due to multiple comparisons, p≤0.01 considered statistically significant).
†Medications from different category but with similar action on certain receptor type.
‡Includes those used for cardiovascular and urinary indications.
EFS, electrical field stimulation; NSAIDs, non-steroidal anti-inflammatory drugs.
Figure 3  Expression of myenteric neuronal markers in ascending and descending colon. Panel A shows representative staining examples from the adult (35–60 years of age) and elderly group (≥70 years) for each region of colon, using antibodies for human neuronal protein C/D (HuC/D), choline acetyltransferase (ChAT) and neuronal nitric oxide synthase (nNOS). Images were captured using NDP View version 2.3.1. Black scale bar is 250 µm. Counting was performed by two independent observers, and the values for each tissue are the mean of these counts. A ganglion was defined as a neural structure containing at least two neurons. The areas counted as neurons were between the circular and longitudinal muscle layers and represented areas of dark brown perikaryal staining in a cell that contained a nucleus (granular stain must cover the nucleus OR encircle at least 50% of circumference of the nucleus AND at least some cytoplasmic granular brown staining must be present). If the staining overlapped or appeared as a continuous area of dark brown staining, in the presence of two distinct nuclei and cell membranes, this was counted as two cell bodies; if there was ambiguity about the presence of a nucleus, the cell was not included. Panel B shows the number of ganglia and number of neuron cell bodies per millimetre of myenteric plexus (using the pan-neuronal cell body marker HuC/D) for adult (□) and elderly (■) ascending and descending (respectively ○ and ⋄) colon. Panel C is arranged similarly and shows the numbers of neuron cell bodies per millimeter of myenteric plexus stained by the antibody for ChAT or nNOS. In Panels B and C, the data are expressed as means±SEM; n=8 adult ascending, 9 elderly ascending, 9 adult descending and 10 elderly descending colon for each stain. These were analysed using analysis of variance with Sidak’s multiple comparison tests; *P<0.05; **P<0.01, only where indicated. PGP9.5, protein gene product 9.5.
differentiation for anti-ChAT was less strong. Nevertheless, in the elderly, the numbers of ChAT-immunolabelled neurons were consistently and significantly greater in ascending colon (figure 3C) but unchanged in descending colon. There were no statistically significant age-related differences in numbers of neurons expressing nNOS for either region (figure 3C). Post hoc calculation of statistical power (Stata SE v14.0) for the observed difference in ChAT immunostaining between adult and elderly ascending colon was 0.97 (expressed alternatively, only five patients would be required in each group to detect the observed difference with a power of 0.8). For the observed difference in HuC/D staining between ascending and descending colon, the post hoc power was 0.82.

Densitometric analysis of intramuscular nerve fibre bundles
In adults, the density of anti-PGP9.5 immunostaining within muscle was generally greater in descending, compared with ascending colon (figure 4B). In ascending colon of the elderly, the density of anti-PGP9.5 staining was unchanged compared with the adults. In descending colon of the elderly, the density was reduced only in deep circular muscle (figure 4B).

Cholinergic enzymes
In ascending colon there were no age-dependent differences in expression, specific activity or overall function of ChAT, although in descending colon ChAT function was greater in the elderly (expression unchanged), tending to increase specific activity (table 5). There were no age-dependent differences in AChE or BChE function in either region of colon (table 5).

Mechanisms: functional
Age-dependent/region-dependent reduction in cholinergic, not nitrogentic functions
In ascending colon of both age groups, L-NAMe 300 µM increased the magnitude of cholinergically mediated contractions during EFS, but this was barely evident in descending colon; after-contractions were not significantly changed (figure 5 shows the magnitude of response; online supplementary file 6 shows percentage change). However, in ascending colon from the elderly, the increase in contractions was smaller compared with the adults (p<0.05; figure 5C; ascending colon from, respectively, n=14/25 adult/elderly patients; descending colon from 16/23 adult/elderly).

Atropine 1 µM revealed or enhanced nitrogeneric mediated muscle relaxation and decreased the magnitude of after-contractions (figure 5D). Comparing the age groups, there were no statistically significant differences in magnitudes of muscle relaxations or after-contractions evoked by EFS during the presence of atropine, in either region of colon (figure 5F; ascending colon from, respectively, n=6/6 adult/elderly and descending colon from 8/5 adult/elderly).

No age-dependent changes in muscle function
Advancing age did not influence contractions evoked by carbachol or Bay-K8644 in either region of colon (carbachol: respectively, n=7/7 and 8/12 ascending/descending colon from adult and elderly; Bay-K8644: n=5 each), nor relaxations evoked by SNP (table 6).

DISCUSSION
This is the first large-scale study into the effects of advancing age on both neuromuscular anatomy and functions in human colon. It identified an age-dependent decline in cholinergic, not nitrogentic, function but surprisingly, only in ascending colon. Paradoxically, the numbers of myenteric neurons staining positively for anti-ChAT increased in the same region, but there was no overall change in neuron count between adult and elderly patients.

The study was needed because human colon has important differences in anatomy and functions compared with mammals in which age research is usually conducted.13 23 Further, in those age-related studies undertaken using human colon, data are inconsistent.14–16 This may be because small numbers were used, insufficient to overcome genetic differences and human variation (especially among the elderly, with longer exposure to lifestyle factors affecting bowel function). Inconsistencies are also created by studying only ascending or descending/sigmoid colon; each has different primary functions (respectively, fermentation of unabsorbed polysaccharides with water/nutrient absorption and storage of faeces prior to defecation), embryological origin and molecular profile.24 Finally, to draw appropriate conclusions, analysis of changes in both anatomy and functions is desirable. Thus, the high reserve capacity of the enteric nervous system (ENS) (in animals) means that functions of the whole organ are not represented by investigations into only structure (eg, neuron numbers) or functions of individual cell types.

The study began with a simple, large-scale assessment of the overall neuromuscular functions of ascending and descending colon, in which tissues were exposed to EFS at a frequency evoking clear neurally mediated changes in muscle contracility. In adult colon from both regions EFS usually caused contraction, followed by ‘after-contraction’ on termination of the stimulus. The contraction during EFS was cholinergically mediated, attenuated by simultaneous inhibitory nitrogeneric activation, their dominance being consistent with greater numbers of myenteric neurons in human colon staining for ChAT or nNOS.25 However, in the elderly, EFS was increasingly likely to evoke muscle relaxation in ascending colon. This difference

| Table 4 | Summary of ganglia and cell bodies stained by antibodies for HuC/D, ChAT and nNOS per millimetre myenteric plexus in different regions of colon from patients of different age groups |
|---|---|---|---|
| Numbers per mm of myenteric plexus | Age group and region of colon | Adult ascending (8) | Elderly ascending (9) | Adult descending (9) | Elderly descending (10) |
| HuC/D ganglia/mm | 1.4±0.1 | 1.7±0.2 | 2.1±0.2* | 2.0±0.1 |
| HuC/D neurons/mm | 7.0±0.9 | 10.2±0.9 | 22.9±5.5† | 15.7±1.5 |
| ChAT neurons/mm | 2.4±0.3 | 5.0±0.6† | 5.2±0.8§ | 4.9±0.8 |
| nNOS neurons/mm | 3.8±0.4 | 5.3±0.8 | 6.6±0.8 | 6.2±0.8 |

The data are expressed as means±SEM. Differences between the two age groups and regions of colon were analysed using analysis of variance with Sidak’s multiple comparison tests.

*P<0.01 (between regions).
†Note the existence of an outlier observation among the HuC/D measurements (neurons/mm) in adult descending colon, which could not be excluded (see figure 3).
‡P<0.05 (between age groups).
§P<0.05 (between regions).
ChAT, choline acetyltransferase; HuC/D, human neuronal protein C/D; nNOS, neuronal nitric oxide synthase.
Figure 4  Density of neuronal innervation within muscle layers. Panel A shows representative examples from protein gene product 9.5 (PGP9.5) stained paraffin-embedded sections of human colon muscle. Images were captured using NDP View version 2.3.1. Densiometric analysis was performed on filtered images converted to black and white, and the percentage density of staining measured over 400×400 pixel excerpts, as shown in the boxes, from the circular muscle (CM) near the myenteric plexus (MP), the deeper CM and the longitudinal muscle (LM), on a fixed magnification of 10×, using ImageJ. For each patient, four sections were analysed and for each region of muscle, two different fields were examined in each of the four sections by two separate assessors. Panel B shows the density of PGP9.5-positive nerve fibres in the adult (35–60 years of age; □) and elderly (≥70 years; ■) groups within ascending and descending colon, n=7 adult and n=8 elderly ascending colon and, respectively, 10 and 9 adult and elderly descending colon. Both assessors identified the same statistically significant changes or trends in the elderly (online supplementary data file 1). These data are expressed as means±SEM and were analysed using analysis of variance with Sidak’s multiple comparison test, *P<0.05; **P<0.01.
was largely uninfluenced by concurrent disease or medications, systematically analysed (unlike previous studies) as potentially confounding covariates. Thus, although it remains a possibility that other factors not measured could have influenced the data (eg, poor glycaemic control, inclusion of premenopausal/postmenopausal women among the younger group, asymptomatic diverticulosis), it seems reasonable to conclude that the data support an age-dependent change in neuromuscular functions in ascending but surprisingly not in descending colon.

Additional substudies were conducted to determine the mechanisms of change in the same cohort of patients. First, we looked for changes in numbers and phenotype of myenteric neurons. Counting of neurons requires strict application of defined criteria, performed blind to subject status. In this study, 306 myenteric neurons were counted in 36 patients; anti-HuC/D and anti-PGP9.5 assessed, respectively, myenteric ganglia/neuron cell bodies, these authors found no age-dependent changes in density of PGP9.5-staining neurons. In spite of the decline in neuron cell bodies staining for nNOS. Here, the different findings may be attributed to differences in method (whole mount vs paraffin sections) and/or presentation of data. In our study, we compared two age groups. Bernard et al tested for linear trends, with most patients showing similar numbers of HuC/D-staining neurons. In spite of the decline in neuron cell bodies, these authors found no age-dependent changes in density of PGP9.5 staining of intramuscular axon bundles.

In the present study, there were relatively more nNOS-staining neurons within ascending colon (confirming others), but no age-related changes in ascending or descending colon. These data are consistent with the suggestion that enteric nitrergic neurons do not exhibit age-related loss. In unspecified regions of colon from patients of advanced age, others report higher percentage of nitrergic neurons with no changes in numbers of calretinin-expressing neurons. The present study indicates that ChAT is found in ~30% of myenteric neuron cell bodies, and density of PGP9.5 staining within the muscle, compared with ascending colon (consistent with previous studies), and increasing age did not change these numbers. However, others reported a decline in numbers of myenteric ganglia and neurons in elderly human colon and small intestine. The relatively small numbers of tissues studied and different staining techniques may explain this difference. In the largest previous study, Bernard et al found a decline in numbers of myenteric neuron cell bodies in descending and sigmoid colon staining for HuC/D, ChAT and PGP9.5, but no change in numbers of cell bodies staining for nNOS. Here, the different findings may be attributed to differences in method (whole mount vs paraffin sections) and/or presentation of data. In our study, we compared two age groups. Bernard et al tested for linear trends, with most patients showing similar numbers of HuC/D-staining neurons. In spite of the decline in neuron cell bodies, these authors found no age-dependent changes in density of PGP9.5 staining of intramuscular axon bundles.

In the present study, there were relatively more nNOS-staining neurons within ascending colon (confirming others), but no age-related changes in ascending or descending colon. These data are consistent with the suggestion that enteric nitrergic neurons do not exhibit age-related loss. In unspecified regions of colon from patients of advanced age, others report higher percentage of nitrergic neurons with no changes in numbers of calretinin-expressing neurons. The present study indicates that ChAT is found in ~30% of myenteric neuron cell bodies, and density of PGP9.5 staining within the muscle, compared with ascending colon (consistent with previous studies), and increasing age did not change these numbers. However, others reported a decline in numbers of myenteric ganglia and neurons in elderly human colon and small intestine. The relatively small numbers of tissues studied and different staining techniques may explain this difference. In the largest previous study, Bernard et al found a decline in numbers of myenteric neuron cell bodies in descending and sigmoid colon staining for HuC/D, ChAT and PGP9.5, but no change in numbers of cell bodies staining for nNOS. Here, the different findings may be attributed to differences in method (whole mount vs paraffin sections) and/or presentation of data. In our study, we compared two age groups. Bernard et al tested for linear trends, with most patients showing similar numbers of HuC/D-staining neurons. In spite of the decline in neuron cell bodies, these authors found no age-dependent changes in density of PGP9.5 staining of intramuscular axon bundles.

In the present study, there were relatively more nNOS-staining neurons within ascending colon (confirming others), but no age-related changes in ascending or descending colon. These data are consistent with the suggestion that enteric nitrergic neurons do not exhibit age-related loss. In unspecified regions of colon from patients of advanced age, others report higher percentage of nitrergic neurons with no changes in numbers of calretinin-expressing neurons. The present study indicates that ChAT is found in ~30% of myenteric neuron cell bodies, and density of PGP9.5 staining within the muscle, compared with ascending colon (consistent with previous studies), and increasing age did not change these numbers. However, others reported a decline in numbers of myenteric ganglia and neurons in elderly human colon and small intestine. The relatively small numbers of tissues studied and different staining techniques may explain this difference. In the largest previous study, Bernard et al found a decline in numbers of myenteric neuron cell bodies in descending and sigmoid colon staining for HuC/D, ChAT and PGP9.5, but no change in numbers of cell bodies staining for nNOS. Here, the different findings may be attributed to differences in method (whole mount vs paraffin sections) and/or presentation of data. In our study, we compared two age groups. Bernard et al tested for linear trends, with most patients showing similar numbers of HuC/D-staining neurons. In spite of the decline in neuron cell bodies, these authors found no age-dependent changes in density of PGP9.5 staining of intramuscular axon bundles.

In the present study, there were relatively more nNOS-staining neurons within ascending colon (confirming others), but no age-related changes in ascending or descending colon. These data are consistent with the suggestion that enteric nitrergic neurons do not exhibit age-related loss. In unspecified regions of colon from patients of advanced age, others report higher percentage of nitrergic neurons with no changes in numbers of calretinin-expressing neurons. The present study indicates that ChAT is found in ~30% of myenteric neuron cell bodies, and density of PGP9.5 staining within the muscle, compared with ascending colon (consistent with previous studies), and increasing age did not change these numbers. However, others reported a decline in numbers of myenteric ganglia and neurons in elderly human colon and small intestine. The relatively small numbers of tissues studied and different staining techniques may explain this difference. In the largest previous study, Bernard et al found a decline in numbers of myenteric neuron cell bodies in descending and sigmoid colon staining for HuC/D, ChAT and PGP9.5, but no change in numbers of cell bodies staining for nNOS. Here, the different findings may be attributed to differences in method (whole mount vs paraffin sections) and/or presentation of data. In our study, we compared two age groups. Bernard et al tested for linear trends, with most patients showing similar numbers of HuC/D-staining neurons. In spite of the decline in neuron cell bodies, these authors found no age-dependent changes in density of PGP9.5 staining of intramuscular axon bundles.
**Figure 5** Age-dependent changes in cholinergic and nitrergic responses to electrical field stimulation (EFS) in human ascending and descending colon. EFS was applied at 5 Hz and at 50 V for 10 s every 1 min, in the absence and presence of Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME) 300 µM or atropine 1 µM. Panels A and D show examples of original traces showing the effects of, respectively, L-NAME and atropine in the adult and elderly ascending colon. Similarly, panels B and E show examples of original traces for both treatments in the adult and elderly descending colon. Panels C and F show the data for each treatment in each region of adult (35–60 years of age; □) and elderly (≥70 years; ■) colon, for each tissue tested. The data are expressed as g tension/g wet weight of tissue generated during and after termination of EFS, together with the mean±SEM contractile force. Respectively, n=14/6 and 7/4 (response generated during/after termination of EFS in the presence of L-NAME and atropine for adult ascending colon), 25/6 and 14/6 (elderly ascending colon), 16/8 and 14/8 (adult descending colon) and 23/5 and 15/5 (elderly descending colon); note that after-contractions did not always occur so their n values are smaller than for the responses measured during EFS. These were analysed using analysis of variance with Sidak’s multiple comparison tests; *P<0.05 only where indicated.
There were no statistically significant differences between values obtained using adult ascending and descending colon or when these values were compared with the elderly (p>0.10 each).

The effects of SNP were un influenced by breakdown in the presence of haemoglobin to form cyanide and methaemoglobin in addition to NO (each can affect tissue viability) — thus, the magnitude of relaxation evoked by SNP 100 µM in ascending colon was not different to that evoked by the NO donor, diethylamine NONOate 10 µM (respectively, 1.3±0.5 and 1.4±0.4 g/g, n=6 each, p=0.8).

Consistent, concentration-dependent relaxations could not be obtained in descending colon.

EFS, electrical field stimulation; L-NAME, N\textsubscript{-}nitro-L-arginine methyl ester hydrochloride; NO, nitric oxide; SNP, sodium nitroprusside.

### Data are expressed as mean±SEM muscle tension/g of tissue (when using the single concentration of Bay-K8644) or when concentration–response curves were constructed, as the pEC\textsubscript{50} and E\textsubscript{max} values derived from these curves (see online supplementary file 3 for carbachol concentration–response curves in female/male, adult/elderly ascending and descending colon). There were no statistically significant differences between values obtained using adult ascending and descending colon or when these values were compared with the elderly (p>0.10 each).

### Table 6 Contractions and relaxations of the muscle in adult (35–60 years of age) and elderly (≥70 years) human ascending and descending colon

<table>
<thead>
<tr>
<th>Compounds causing muscle contraction*</th>
<th>Adult (n=7)</th>
<th>Elderly (n=7)</th>
<th>Adult (n=8)</th>
<th>Elderly (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbachol 0.001–10 µM</td>
<td>pEC\textsubscript{50}=6.5±0.5</td>
<td>E\textsubscript{max}=50±10 g/g</td>
<td>pEC\textsubscript{50}=6.2±0.3</td>
<td>E\textsubscript{max}=43±6 g/g</td>
</tr>
<tr>
<td>Bay-K8644 1 µM (in presence of L-NAME 300 µM)</td>
<td>16±2 g/g</td>
<td>n=5</td>
<td>17±2 g/g</td>
<td>n=5</td>
</tr>
<tr>
<td></td>
<td>E\textsubscript{max}=25±2 g/g</td>
<td>n=5</td>
<td>E\textsubscript{max}=13±2 g/g</td>
<td>n=5</td>
</tr>
</tbody>
</table>

### Compounds causing muscle relaxation

<table>
<thead>
<tr>
<th>SNP</th>
<th>Adult (n=5)</th>
<th>Elderly (n=5)</th>
<th>Adult (n=10)</th>
<th>Elderly (n=12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.01–1000 µM</td>
<td>pEC\textsubscript{50}=6.5±0.8</td>
<td>E\textsubscript{max}=1.7±0.2 g/g</td>
<td>pEC\textsubscript{50}=6.4±0.6</td>
<td>E\textsubscript{max}=1.9±0.2 g/g</td>
</tr>
<tr>
<td>SNP†</td>
<td>13±3 g/g</td>
<td>n=5</td>
<td>E\textsubscript{max}=45±6 g/g</td>
<td>n=12</td>
</tr>
</tbody>
</table>

Data represent the most complete set of normative data for the human ENS (a recent systematic review identified marked diversity in quantification of human ENS markers among numerous small studies), (2) refute previous observations with smaller numbers and quantification of human ENS markers among numerous small studies, (3) pose a new hypothesis meriting further study, namely that a region-dependent decline in cholinergic functions could be associated with increased somal ChAT-immunoreactivity and other neurons was preceded by increased number of ChAT-immunoreactive neurons. In the present experiments, the increased detection of ChAT-immunoreactive cell bodies may therefore reflect reduced axonal transport of the enzyme away from the cell body following age-related damage to axonal transport. Experiments are required to test this hypothesis. The relatively poor signal-to-background for the ChAT antibody precludes meaningful analysis of ChAT expression by nerve terminals within the muscle, but perhaps choline uptake/ACH release could be measured during nerve stimulation in human colon.

In the first of additional functional studies, cholinergic and nitrergic functions were isolated by, respectively, L-NAME and atropine. During the presence of L-NAME, cholinergically mediated contractions evoked by EFS in ascending colon from the elderly were smaller compared with adults. A similar difference was not observed in descending colon. In the presence of atropine, nitrergically mediated relaxations were not changed with increasing age in either region of colon. These data suggest that the age-related changes in function observed in the larger functional study (see above) were due to region-dependent decline in cholinergic function, which in ascending colon enabled an intact nitrergic function to become dominant. This change was not due to reduced ability of the muscle to contract (in response to carbachol or Bay-K8644, also refuting the possibility of compensatory age-dependent changes in muscarinic receptor density) or relax (in response to SNP). Others reported a greater maximal response to carbachol in sigmoid colon from females, compared with males (~60 years), with elderly females (mid-70s) being more sensitive; by contrast, EFS-evoked contractions and the effect of L-NAME on these responses were greater in elderly males. However, several muscle strips were used from the same patient, n values representing numbers of preparations, not patients; the potential for unintentional bias is therefore high. The present data also contrast with a reported age-dependent increase in ability of human colon muscle cells to contract in response to different ligands, including carbachol; perhaps enzyme digestion influences how cells respond.

In summary, the size and design of the study aimed to accept, control and understand state and trait variability. The data (1) represent the most complete set of normative data for the human ENS (a recent systematic review identified marked diversity in quantification of human ENS markers among numerous small studies), (2) refute previous observations with smaller numbers of patients, notably the existence of age-related changes in muscle function and in neuron numbers within the colon, (3) pose a new hypothesis meriting further study, namely that a region-dependent decline in cholinergic functions could be associated with increased somal ChAT staining caused by reduced axonal transport and (4) indicate that findings from laboratory animals do not always translate to humans, species-dependent variability being additionally hampered by gross differences in lower bowel anatomy and failure to consider that different bowel regions may age differently. Several questions remain unanswered. What causes the loss of cholinergic function and why only in ascending colon? Possible mechanisms include age-related intestinal inflammation, susceptibility to reactive oxygen species and loss of trophic support from glial cells. In the present study, there was no age-associated difference in gross inflammatory status, but more sensitive measurements are needed (eg, assessment of age-dependent changes in ‘proinflammatory’ status of macrophages and analysis of immune activity of dendritic cell subsets in different regions of human colon). Interestingly, the high content of living bacteria in ascending colon may change in composition among the elderly, promoting low-grade inflammation (inflammaging) and increasing metabolic activity. As such, it is important to consider the potential for age-related changes in the human colon that may contribute to the progression of gastrointestinal disease.
mucosal permeability to allow potentially damaging substances to penetrate into the wall of ascending colon. Precedents for age-related, region-specific reductions in cholinergic functions (and increased ChAT; see Discussion above) exist in brain of patients with mild cognitive impairment[34,43] and in aged rats[46]. Notably, none of the patients studied had previous clinical diagnosis of constipation (any history of self-reporting constipation was not obtained). It is, therefore, not possible to conclude that declined myenteric cholinergic function within the ascending colon necessarily leads to clinical constipation. Indeed, other degenerative changes are suggested to contribute to age-related constipation (including changes in inhibitory junction potentials within the descending colon ENS[37], enteric sensory[3] and extrinsic sensory innervations[35]). Nevertheless, the reduced cholinergic function does support the view that the ENS reserve capacity is reduced in the elderly, increasing sensitivity to lifestyle changes affecting intestinal functions (eg, diet, exercise, medications; see the Introduction section) and raising the probability of developing constipation. A similar argument has been suggested for cholinergic function in a more generalised brain age, in which the consequence of a gradual decline in synthesis and/or release of ACh from synaptosomes[39] only becomes apparent when nerves are stressed or damaged.[31]

Acknowledgements We thank other consultant colorectal surgeons, particularly Chris Chan, and pathologists at Barts Health for assisting with identification of patients for recruitment into this study and for providing tissue suitable for laboratory use.

Contributors JB and VWSK conducted the experiments, SE and CHK facilitated the identification, collection and governance of human tissue collection, TD-S, JEM and MJS provided methodology guidance, GIS wrote the manuscript and all authors participated in its construction and refinement, particularly CHK, VWSK, JB and MJS.

Funding JB was supported by the Bowel and Cancer research charity, the Dunhill Medical Trust (grant no: R382/1114 to CHK, CHK and MJS) and an EMBO scholarship to visit the Karolinska Institutet (to JB). VWSK was supported by the research into ageing fund, set up and managed by AgeUK (grant to GIS). AP and SE are supported by Takeda Pharmaceuticals.

Competing interests GIS is currently in receipt of funding from Takeda Pharmaceuticals, BBSRC together with GlaxoSmithKline, Benevolent and the Dunhill Foundation. He acts as an advisor to Takeda Pharmaceuticals and to Zealand Pharma.

Patient consent Not required.

Ethics approval Approved by the local ethics committee (REC 10/H0703/71).

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
Neurogastroenterology


